Congratulations to Dr. Nate Shannon on his recently published manuscript! Lots of exciting findings to follow up on related to Miro1 and mitochondrial positioning. journals.biologists.com/jcs/…
Congrats to Nate on an excellent thesis!
Congrats Nathaniel Shannon, #UVMLarnerMed CMB graduate Ph.D. candidate, who successfully defended his dissertation, “The Role Of Miro1 Mediated Mitochondrial Positioning On Redox...” Pictured (left) w/ advisor @BrianCunniff, Ph.D.
@CunniffLab
@UVMResearch
@uvmcmb
@UVMGradCollege
Come check out PhD candidate Victoria Gibson discuss the importance of Peroxiredoxin 3 in mesothelioma tumors at #SfRBM2024. SYMPOSIA SESSION 3: Unveiling the Therapeutic Potential: Exploring Redox Signaling from Fundamentals to Drug Targets 2:45pm @RedoxVT @RSOncologyLLC @SFRBM
PhD Candidate Nate Shannon's first author paper out as a pre-print. Very proud of Nate! Some very interesting DEGs dependent on Miro1 expression and an interesting and evolving cell cycle/ERK1/2 story! @UVMcancercenter @RedoxVT #mitochondria
biorxiv.org/content/10.1101/…
Cunniff Lab retweeted
NEW @NatureCellBio study finds glutathione S transferase theta drives pancreatic cancer metastasis by targeting fibronectin which places redox reactions front and center in tumor metastatic behavior.
Congrats @RedoxVT on supporting these findings!
go.nature.com/4aVXWAE
Come chat at the booth, we have warm cookies!
Meet us today June 2nd to hear Brian Cunniff, our CSO, talk about #mitochondrial dysfunction in cancer and how PRX3 plays a role. Booth #23094 #ASCO24 #cancerresearch @CunniffLab
Excited to see Dean present exciting data around the Phase 1 trial of RSO-021 at #ASCO24. A redox-dependent cancer therapy currently being tested in Phase 2! @RedoxVT @UVMcancercenter @dean_fennell @RSOncologyLLC xitter.cf/RSOncologyLLC/status/1…
Cunniff Lab retweeted
#ASCO24 Abstracts have been published! See the short list of rapid oral abstracts in Developmental Therapeutics - Molecularly Targeted Agents & Tumor Biology and you will see our first-in-human phase 1 for RSO-021 @dean_fennell @CunniffLab @PRCLeicester
tinyurl.com/ASCO24
Much deserved @dean_fennell !
Congratulations @dean_fennell, very much deserved. You lead a great team, it’s a privilege to be part of it and a pleasure working alongside you.
le.ac.uk/news/2024/may/dean-…
Congrats to @RSOncologyLLC for this much deserved recognition at #ASCO24 . Looking forward to @dean_fennell giving and exciting talk! @RedoxVT
RSO-021 novel therapy and first-in-human clinical trial outcomes🫁will be presented on June 3rd at #ASCO24 with @dean_fennell #CancerResearch @BrianCunniff @UVMcancercenter
finance.yahoo.com/news/rs-on…
Always an excellent meeting with great science and clinical progress being showcased! @RedoxVT @UVMcancercenter @RSOncologyLLC
Looking forward to presenting our new data in support of the anti-cancer activity of RSO-021, lots of fresh discoveries! @RedoxVT @dean_fennell @UVMcancercenter
Gearing up for #SanDiego next month. But you won't find us on the beach April 7th or 9th, since we will be presenting our posters at @AACR 2024. Add us to your itinerary to see our 🐭preclinical anticancer activity #Mesothelioma #CancerResearch @BrianCunniff @dean_fennell
Cunniff Lab retweeted
Happy to announce our abstract has been approved 👏👏 #BTOG24 Our CSO Brian Cunniff, Phd, @CunniffLab will be presenting "First-in-class peroxiredoxin 3 (PRX3) inhibitors" poster. Stop by the welcome reception Wednesday April 17th, 18:30 – 20:00, say hello or ask questions.
Cunniff Lab retweeted
Happy to share our review with @echouchani on recent advances in cysteine proteomics! @HarvardCellBio @DFCI_CancerBio
authors.elsevier.com/c/1idmT…
Exciting news! @RedoxVT
BIG NEWS! Groundbreaking anticancer drug moves to phase 2 expansion study @dean_fennell @CR_UK @STS_CTsurgery @asthmalunguk @LeicesterCTU
businesswire.com/news/home/2…
Cunniff Lab retweeted
We are proud to announce we have 2 abstracts accepted for the @AACR Annual Meeting 2024 in San Diego. 👏 We will present our posters in session "Other Cellular Mechanisms for Anticancer Drug Action" and "Cellular Stress Responses 1"
See you in🌞SD! @CunniffLab @dean_fennell
Cunniff Lab retweeted
Our team presenting our MITOPE phase 2 study of novel therapies for #mesothelioma and #lungcancer with malignant pleural effusions to #nurses at @HASAG education workshop in #London 👏
PhD candidate Nate Shannon presenting his exciting data in which ERK1/2 activity is dysregulated in response to perinuclear mitochondrial clustering via Miro1 deletion. Great work, Nate!
Come learn more about our work tomorrow at 1:00pm at #cellbio2023 in the Subgroup: Energy and Metabolism in Time and Space . See you in Boston!
The Butler Family Foundation is raising money for mesothelioma research with an online auction of some very cool items/experiences. We are very grateful for their continued support! Get yourself some court-side Knicks tickets and support Meso research!
butlerfoundation.betterworld…















